1. Data on file. Available from CSL Behring as DOF PVG-006.
  2. Immune Deficiency Foundation (IDF). About primary immunodeficiencies. Accessed August 3, 2022.
  3. Immune Deficiency Foundation (IDF). Specific diseases. Accessed August 3, 2022.
  4. Immune Deficiency Foundation (IDF). Immunoglobulin (Ig) Replacement Therapy. Accessed August 3, 2022.
  5. Berger M. Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose. Curr Opin Allergy Clin Immunol. 2011;11(6):532-538.
  6. Siegel J. IVIg medication safety: a stepwise guide to production selection and use. Pharm Pract News. Dec 2010.
  7. Siegel J. Immune globulins: therapeutic, pharmaceutical, cost, and administration considerations. Pharm Pract News. Jan 2010.
  8. GBS/CIDP Foundation International. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 101. Accessed June 20, 2022.
  9. US Dept of Health and Human Services. National Institutes of Health. National Heart, Lung, and Blood Institute. Chronic inflammatory demyelinating polyneuropathy (CIDP). Accessed June 20, 2022.
  10. US Dept of Health and Human Services. National Institute of Health. National Heart, Lung and Blood Institute. Immune Thrombocytopenia (ITP). Accessed June 20, 2022.
  11. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Advances. 2019;3(23):3829-3866.
  12. Neunert C, Lim K, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;17(6):4190-4207.
  13. Robak T, Salama A, Kovaleva L, et al. Efficacy and safety of Privigen®, a novel liquid intravenous immunoglobulin formulation in adolescent and adult patients with chronic immune thrombocytopenic purpura. Hematology. 2009;14(4):227-236.
  14. US Dept of Health and Human Services. National Institutes of Health. National Heart, Lung, and Blood Institute. How is (ITP) treated? Accessed June 20, 2022.
  15. National Institutes of Health: Safety and efficacy of intravenous immunoglobulin IgPro10 in patients with primary immunodeficiencies. /results/NCT00322556. Accessed June 20, 2022.
  16. Stein MR, Nelson RP, Church JA, et al. Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies. J Clin Immunol. 2009;29(1):137-144.
  17. Data on file. Available from CSL Behring as DOF PVG-003.
  18. Cramer M, Frei R, Sebald A, Maeder M. Stability over 36 months of new liquid 10% polyclonial immunoglobulin product (IgPro10. Privigen®) stabilized with L-proline. Vox Sang. 2009;96(3):219-225.
  19. Bolli R, Woodtli K, Bärtschi M, Höfferer L, Lerch P. L-Proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions. Biological. 2010;38(1):150-157.
  20. Hagan JB, Fasano MB, Spector S, et al. Efficacy and safety of new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immunol. 2010;30(5):734-745.
  21. Sun A, Teschner W, Yel L. Improving patient tolerability in immunoglobulin treatment: focus on stabilizer effects. Expert Rev Clin Immunol. 2013;9(6):577-587.
  22. Simon HU, Späth PJ. IVIG mechanisms of action. Allergy. 2003;58(7):543-552.
  23. Maddur MS, Lacroix-Desmazes S, Bayry J, Kaveri SV. Intravenous polyclonal immunoglobulin in autoimmune diseases: clinical indications and mechanisms of action. Drug Discov Today Ther Strateg Autoimmun. 2009;6(1):5-11.
  24. Jacob S, Rajabally Y. Current proposed mechanism of action of intravenous immunoglobulins in inflammatory neuropathies. Curr Neuropharmacol. 2009;7(4):337-342.
  25. Imbach P, Lazarus AH, Kühne T. Intravenous immunoglobulin induce potentially synergistic immunomodulations in autoimmune disorders. Vox Sang. 2009;98(3):385-394.
  26. Centers for Disease Control and Prevention. National Center for Health Statistics--ICD-10-CM. Accessed June 20, 2022.
  27. CPT Code 96365. Codify by AAPC. Accessed June 20, 2022.
  28. CPT code 96366. Codify by AAPC. Accessed June 20, 2022.
  29. HCPCS Code S9338. Codify by AAPC. Accessed June 20, 2022.
  30. HCPCS Code J1459. Codify by AAPC. Accessed June 20, 2022.
  31. Kobrinsky L. Prevalencer and morbidity of primary immunodeficiency diseases, United States 2001-2007. J Clin Immunol. 2014 November;34(8):954-961. doi:10.1007/s10875-014-0102-8.
You are now leaving the current website.

Do you want to continue?